Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Roheena Z. Panni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8144-6869; OpenAlex author ID A5050185725. Sources: ClinicalTrials.gov.

Their work

Papers
12
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 trial · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 12

  1. Adaptive Salvage Stereotactic Radiation for Locoregional Recurrence of Pancreatic Adenocarcinoma After Surgery. Co-author DOI 10.1016/j.prro.2026.03.015↗
  2. Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer. Co-author DOI 10.1126/sciadv.aei1190↗
  3. Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancer. Co-author DOI 10.1126/sciimmunol.adp3978↗
  4. Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1467↗
  5. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Co-author DOI 10.1126/scitranslmed.aau9240↗
  6. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Co-author DOI 10.1038/s41467-018-03600-6↗
  7. Residual Tumor Index: A Prognostically Significant Pathologic Parameter in Neoadjuvant-treated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/pas.0000000000001144↗
  8. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic du… Co-author DOI 10.1136/gutjnl-2017-313738↗
  9. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/s1470-2045(16)00078-4↗
  10. Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Co-author DOI 10.1007/s00262-014-1527-x↗
  11. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Co-author DOI 10.1158/1078-0432.ccr-13-0525↗
  12. A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4236/jct.2013.43096↗

Trials 1

  1. Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients Principal investigator NCT04536077↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David G DeNardo · 9 shared papers, 2013–2026 · strength 0.80
  2. William G. Hawkins · 8 shared papers, 2013–2026 · strength 0.76
  3. Dominic E. Sanford · 7 shared papers, 2013–2026 · strength 0.65
  4. Kian‐Huat Lim · 3 shared papers, 2016–2026 · strength 0.49
  5. Ryan C Fields · 6 shared papers, 2013–2025 · strength 0.48
  6. Carl DeSelm · 2 shared papers, 2026 · strength 0.44
  7. David C. Linehan · 7 shared papers, 2013–2020 · strength 0.37
  8. Andrea Wang‐Gillam · 5 shared papers, 2013–2026 · strength 0.34
  9. Timothy M. Nywening · 4 shared papers, 2016–2020 · strength 0.27
  10. Graham D. Hogg · 2 shared papers, 2019–2025 · strength 0.27
  11. William E. Gillanders · 2 shared papers, 2018–2026 · strength 0.26
  12. Patrick M. Grierson · 1 shared paper, 2026 · strength 0.25
  13. David S. Lakomy · 1 shared paper, 2026 · strength 0.25
  14. Richard Tsai · 1 shared paper, 2026 · strength 0.25
  15. Hyun Jee Kim · 1 shared paper, 2026 · strength 0.25
  16. Michael Richard Waters · 1 shared paper, 2026 · strength 0.25
  17. Felicia Zhang Perkins · 1 shared paper, 2026 · strength 0.19
  18. Feng Gao · 1 shared paper, 2026 · strength 0.19
  19. Elizabeth M. Jaffee · 1 shared paper, 2026 · strength 0.19
  20. Daniel A. Laheru · 1 shared paper, 2026 · strength 0.19
  21. Varintra E. Lander · 1 shared paper, 2025 · strength 0.19
  22. Blake E. Sells · 1 shared paper, 2025 · strength 0.19
  23. Liang‐I Kang · 1 shared paper, 2025 · strength 0.19
  24. Alyssa G. Weinstein · 1 shared paper, 2025 · strength 0.19
  25. Tiantian Liu · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.